The researchers found that adding AZD8931 did not work better than anastrozole alone. The trial recruited 359 women. Their average age was 61. They all had breast cancer that was hormone receptor ...

These complications were considered unlikely to influence the antitumour effects of anastrozole, and no significant difference between treatment groups was observed in the other demographic ...

06) at the 47-month follow-up visit. The overall reduction in incidence of contralateral invasive breast cancer with anastrozole treatment was significant at 33 and 47 months of follow-up (HR 0.30 ...

The trial evaluated switching to the camizestrant combination versus continuing standard-of-care treatment with an aromatase inhibitor (AI) (anastrozole or letrozole) in combination with a CDK4/6 ...

“[Kisqali] plus a NSAI provides treatment benefit to a broad range of patients with ... on/1-week-off schedule for three years plus an NSAI regimen of letrozole or anastrozole for at least five years ...

Almost 30 years after it was first licensed as a treatment for breast cancer, aromatase inhibitor anastrozole has been cleared for preventive use in women at high risk of developing the disease in ...

Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for KISQALI® (ribociclib ...

A month after the Eastern Cape Department of Health promised that they had paid the overdue bills that delayed the delivery of chemotherapy drugs to Nelson Mandela Bay hospitals and that the issue ...

Breast cancer patients whose tumors have spread to other parts of their bodies live from scan to scan. Is their treatment working? Or will they learn their cancer is growing again? But a new study ...